Company Media Room of Tharimmune Inc.

Press Release Aug 20, 2025

Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments

Press Release Aug 13, 2025

Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl

Press Release Aug 5, 2025

Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors

Press Release Aug 4, 2025

Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery

-Company closes approximately $5.47 million in equity financing in 2Q/3Q25
-TH104 potentially fills a critical National Security Need against Weaponized Fentanyl
-TH023 may fulfill the promise of delivering a safe and effective oral antibody medication against inflammation
-Company Strengthens Operational Leadership, Corporate Governance and Accounting

Press Release Jul 23, 2025

Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

Press Release Jun 17, 2025

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

Press Release May 19, 2025

Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

Press Release May 6, 2025

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

Press Release May 1, 2025

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

Press Release Apr 30, 2025

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

Press Release Apr 28, 2025

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

Press Release Apr 15, 2025

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

Press Release Apr 7, 2025

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

Press Release Mar 31, 2025

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

-Received positive feedback on New Drug Application submission via the 505(b)(2) pathway

-Company leveraging existing human pharmacokinetic data with TH104

-Advancing CMC plan to meet requirements of a New Drug Application

Press Release Mar 24, 2025

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

Press Release Mar 4, 2025

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

Press Release Jan 27, 2025

Tharimmune to Present at the Microcap Conference 2025

Press Release Dec 16, 2024

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Press Release Dec 6, 2024

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Press Release Nov 18, 2024

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Press Release Nov 13, 2024

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Press Release Nov 4, 2024

Tharimmune Announces Upcoming Conference Presentations

Press Release Oct 30, 2024

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Press Release Oct 28, 2024

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Press Release Oct 25, 2024

Tharimmune Announces Upcoming Conference Presentations

Press Release Sep 30, 2024

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Press Release Sep 16, 2024

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Press Release Jul 22, 2024

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Press Release Jul 17, 2024

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Press Release Jul 16, 2024

Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104

Press Release Jul 10, 2024

Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor

Press Release Jun 20, 2024

Tharimmune Announces $2.08 Million Private Placement

Press Release Jun 17, 2024

Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

FDA Provides Positive Feedback to Company Regarding TH104 Phase 2 Program

Company Incorporating FDA Feedback into Phase 2 Protocol

Company Believes it is On-track to Initiate Phase 2 Trial

Press Release Jun 10, 2024

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Pharmacokinetic profile of oral transmucosal delivery of TH104 was comparable to intravenous delivery of reference drug

Positive safety/tolerability achieved with TH104 reporting a mild side-effect profile

Planning for Phase 2 trial for moderate-to-severe chronic pruritus in primary biliary cholangitis (PBC) is ongoing and on track to initiate in 2024

Press Release May 29, 2024

Tharimmune to Present at 2024 BIO International Convention

Press Release May 22, 2024

Tharimmune Announces 1-for-15 Reverse Stock Split

Press Release Apr 30, 2024

Tharimmune To Participate in Two Upcoming Investor Conferences in May

Press Release Apr 23, 2024

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

Obtained rights from Washington University to develop and incorporate human HER2 directed antibodies
Complements early pipeline of novel tunable "Knob domain" antibodies for HER2 & HER3

Press Release Apr 15, 2024

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

Press Release Mar 5, 2024

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

Press Release Feb 20, 2024

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Press Release Feb 5, 2024

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Press Release Jan 29, 2024

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

Press Release Dec 11, 2023

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients